Wednesday, April 07, 2021 3:46:26 PM
flipper44, I know you don't want any guesses, but I don't believe anyone outside of senior management at NWBio would know for 100% sure.
Here is my guess / hope, this hire will help provide a point-person in Canada if in fact NWBio is using the FDA's Real Time Oncology Review (RTOR) and the Project Orbis programs for concurrent BLA review and approval of DCVax-L in the UK, the US and Canada.
NWBio has Europe covered with Dr. Marnix Bosch moving back to the Netherlands, now we have Kristyn Power on the ground in Canada.
NWBio already has excellent representation and coverage of the FDA in the US, which is located in Silver Springs, Maryland at:
10903 New Hampshire Ave, Silver Spring, MD 20903
This is only about 10 miles from NWBio's corporate headquarters in Bethesda, Maryland:
Here is my guess / hope, this hire will help provide a point-person in Canada if in fact NWBio is using the FDA's Real Time Oncology Review (RTOR) and the Project Orbis programs for concurrent BLA review and approval of DCVax-L in the UK, the US and Canada.
NWBio has Europe covered with Dr. Marnix Bosch moving back to the Netherlands, now we have Kristyn Power on the ground in Canada.
NWBio already has excellent representation and coverage of the FDA in the US, which is located in Silver Springs, Maryland at:
10903 New Hampshire Ave, Silver Spring, MD 20903
This is only about 10 miles from NWBio's corporate headquarters in Bethesda, Maryland:
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
